Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 565 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cequa Clear all

Conditions: Ulcerative Colitis
Interventions: Ozanimod, Conventional therapy, Advanced therapy; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 2,828 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 1
States / cities: Eden Prairie, Minnesota

Conditions: Kidney Transplantation
Interventions: cyclosporine, Prograf (Tacrolimus); Drug
Lead sponsor: East Carolina University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Anemia, Aplastic
Interventions: Sirolimus, Cyclosporine; Drug
Lead sponsor: Office of Rare Diseases (ORD); NIH
Eligibility: 21 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 4
States / cities: Los Angeles, California • Tampa, Florida • Cleveland, Ohio + 1 more

Conditions: Healthy
Interventions: Danicopan, Cyclosporine, Tacrolimus, Calcium Carbonate, Aluminum/Magnesium Hydroxide/Simethicone, Omeprazole; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Kidney Transplantation
Interventions: Cyclosporine, CP-690,550; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 37
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 14 more

Conditions: Uveitis
Interventions: fluocinolone acetonide intraocular implant, oral corticosteroid with immunosuppressive agents as needed; Drug
Lead sponsor: JHSPH Center for Clinical Trials; Other
Eligibility: 13 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 21
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 16 more

Conditions: Adenosine Deaminase Deficiency, Autosomal Recessive Disorder, Immune System Disorder, Purine-Nucleoside Phosphorylase Deficiency, Severe Combined Immunodeficiency, Severe Combined Immunodeficiency With Absence of T and B Cells, X-Linked Severe Combined Immunodeficiency
Interventions: Allogeneic Bone Marrow Transplantation, Cyclosporine, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Total-Body Irradiation; Procedure · Drug · Other + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hepatocellular Carcinoma
Interventions: Sorafenib Standard Dosing Regimen, Sorafenib Ramp-Up Regimen; Drug
Lead sponsor: University of Florida; Other
Eligibility: 20 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 9
States / cities: Gainesville, Florida • Jacksonville, Florida • Orlando, Florida + 6 more

Conditions: Dry Eye
Interventions: Cyclosporine A 0.05%, Arificial Tear; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: filgrastim, therapeutic allogeneic lymphocytes, cyclophosphamide, cyclosporine, fludarabine phosphate, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Leukemia, Myelodysplastic Syndromes
Interventions: anti-thymocyte globulin, cyclosporine; Biological · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 15 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 94
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more

Conditions: Graft Versus Host Disease, Aplastic Anemia
Interventions: anti-thymocyte globulin, cyclophosphamide, cyclosporine, methylprednisolone, Allogeneic Bone Marrow Transplantation; Drug · Procedure
Lead sponsor: Northwestern Memorial Hospital; Other
Eligibility: 15 Years to 55 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pediatric Liver Transplantation
Interventions: Corticosteroids, Cyclosporine, mycophenolate mofetil; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 3 Months to 12 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 2
States / cities: San Francisco, California • New York, New York

Conditions: Dry Eye Disease
Interventions: Cyclosporine Ophthalmic Emulsion 0.05%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 16 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Graft Vs Host Disease
Interventions: Placebo, Abatacept; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 2 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 15
States / cities: Duarte, California • Tampa, Florida • Atlanta, Georgia + 8 more

Conditions: Myelodysplastic Syndrome
Interventions: Erythropoietin, Cyclosporin A, G-CSF, Prednisone; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: alemtuzumab, cyclosporine, fludarabine phosphate, melphalan, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 70 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: isavuconazole, cyclosporine; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Leukemia
Interventions: therapeutic allogeneic lymphocytes, cyclosporine, fludarabine, mycophenolate mofetil, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 55 Years to 69 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 83
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 55 more

Conditions: Healthy Volunteer
Interventions: cyclosporine, danoprevir, ritonavir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Cytomegalovirus Infection
Interventions: Letermovir, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 10
States / cities: Duarte, California • Sacramento, California • Miami, Florida + 7 more

Conditions: Aplastic Anemia
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 15 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Aplastic Anemia, Leukemia, Myelodysplastic Syndrome
Interventions: Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine., CliniMACS device; Drug · Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2017
U.S. locations: 6
States / cities: Boston, Massachusetts • New York, New York • Cincinnati, Ohio + 2 more

Conditions: Corneal Neovascularization
Interventions: Subconjunctival aflibercept, Placebo: Standard of care only; Drug · Other
Lead sponsor: Balamurali Ambati; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Salt Lake City, Utah

Search by objective public record fields.

A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their Infants

Optima: Optimizing Prograf Therapy in Maintenance Allografts II

Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia

A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults

Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients

Multicenter Uveitis Steroid Treatment (MUST) Trial

Total-Body Irradiation Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Severe Combined Immunodeficiency Undergoing Donor Bone Marrow Transplant

Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)

The Prophylactic Use of Topical Cyclosporine A 0.05% to Prevent Graft Versus Host Disease Related Dry Eye

Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer

S0020 Immunosuppressive Therapy in Treating Patients With Myelodysplastic Syndrome

Study of Allogeneic Bone Marrow and T-Cell Depleted, CD34+ Peripheral Blood Stem Cell Transplantation in Patients With Aplastic Anemia

Safety, Tolerability and Pharmacokinetics of Oral CellCept (Mycophenolate Mofetil) in Pediatric Liver Transplant Recipients on Concomitant Treatment With Cyclosporine and Corticosteroids

Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%

Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis

Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS

Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

Drug Interaction Study of Isavuconazole and Cyclosporine

S0125, Chemotherapy, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Older Patients With Acute Myeloid Leukemia

A Drug-Drug Interaction Study Between Danoprevir/Low-Dose Ritonavir and Cyclosporine in Healthy Volunteers

Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)

Neuropsychological Effects of Immunosuppressive Treatment in Subjects With Aplastic Anemia

Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine

Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea